Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00654875 · ClinicalTrials.gov registry record · Phase 4

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

A Phase 4 study of Essential Hypertension, sponsored by Novartis.

Completed
Registry status
Phase 4
Development phase
328
Enrollment target
3
Study locations

NCT00654875 is a Phase 4 study of Essential Hypertension that has completed, run by Novartis. The registered enrollment target is 328 participants, below the 763-participant average among 8 other Essential Hypertension trials with a reported enrollment target (57% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00654875, a Phase 4 study of Essential Hypertension, has completed, sponsored by Novartis.

COMPLETED
Registry status
Phase 4
Development phase
328 participants
Enrollment target
3
Study locations

Study Summary

This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension

Conditions Studied

Essential Hypertension

Interventions

  • DRUG Aliskiren
  • DRUG Placebo to Aliskiren

Study Locations (3)

Other

  • Investigative Site - Frankfurt
  • Investigative Site - Valencia

Ohio

  • Investigative Site - Zanesville

Trial Details

FieldValue
Enrollment Target 328 participants
Start Date 2008-03
Est. Completion 2008-11
Phase Phase 4

Sponsor

Novartis

265 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00654875

The ClinicalTrials.gov registry entry for NCT00654875 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 763-participant average among 8 other Essential Hypertension trials with a reported enrollment target (57% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Aliskiren is the first listed.

NCT00654875 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, Ohio.

Frequently Asked Questions

What is clinical trial NCT00654875 about?

NCT00654875 is a clinical study titled "Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.". This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension

What is the current status of trial NCT00654875?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 328 participants. The study started on 2008-03. Estimated completion is 2008-11.

What conditions does trial NCT00654875 study?

This clinical trial studies the following conditions: Essential Hypertension.

What interventions are being tested in trial NCT00654875?

The interventions under investigation include: Aliskiren (DRUG), Placebo to Aliskiren (DRUG).

Who is sponsoring clinical trial NCT00654875?

This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00654875 being conducted?

This trial has 3 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Essential Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Essential Hypertension

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.